Document text
Principal Investigator: TIMOTHY J CARDOZO
Organization: NEW YORK UNIVERSITY SCHOOL OF MEDICINE
Fiscal Year: 2024
Award: $228,825
Funding agency: National Institute of Allergy and Infectious Diseases
Project Summary
An HIV vaccine remains a critical and as yet unrealized asset in the 40-year fight against the HIV/AIDS
pandemic. New insights towards achieving vaccine protection from HIV acquisition may be gained by a
comparative case study of COVID-19 vaccines, which achieved nearly 100% efficacy against a similarly
enveloped, RNA virus with a similarly architected, trimeric, Class I fusion viral spike mechanism. Neutralization
B-cell epitopes exposed at the apex of the SARS-CoV-2 trimeric viral spike correlated clearly and strongly with
protection from viral acquisition, both in humans in the real world/circulating virus setting and in non-human
primate (NHP) preclinical models. We hypothesized that vaccine immunogens could be improved by focusing
antibody responses to two equivalent B-cell epitopes at the HIV/SIV viral spike apex, one an epitope targeted
by neutralizing antibodies (V2b) and one a purely non-neutralization epitope (V2c). In preliminary results, we
showed that removal of the viral spike apical V1 loop segment (DV1-Env) masking the V2c epitope enhanced
protection against viral challenge in both a highly stringent SIV and matched SHIV challenge model, achieving
>90% vaccine efficacy. In further preliminary results, we designed an immunogen displaying only this V2c
epitope in isolation and proved that it was highly immunogenic as an isolated epitope and indeed elicited purely
non-neutralizing antibodies in vivo. The study revealed that V2c contributed to, but was not sufficient on its
own, for protection. In this exploratory study, we pursue the new hypothesis that the combination of the two
HIV, viral-spike apical, B-cell epitopes in a single vaccine can reconstitute an increased level of protection as
observed with COVID-19 vaccines, by synergizing V2c with the V2b neutralization epitope. We will 1) design
and validate a V2b-focused immunogen, and 2) test the precise combination of neutralizing, vaccine-elicited
anti-V2b antibodies with non-neutralizing, cytotoxic, vaccine-elicited V2c antibodies, along with coordinated
cellular immune responses in vivo for their ability to delay viral acquisition as compared to the V2c epitope
alone. Successful results in these two aims could justify a research project on the design and translational
development of a novel, viral-spike-apex-focused, efficacious HIV vaccine.
Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><2019-nCoV vaccine><3-D><3-D structure><3-Dimensional><3-dimensional structure><3D><3D structure><AIDS Virus><AIDS/HIV><Ab-dependent cellular cytotoxicity><Abscission><Acquired Immune Deficiency Syndrome Virus><Acquired Immunodeficiency Syndrome Virus><Animals><Antibodies><Antibody Response><Antigen Variation><Antigenic Determinants><Antigenic Variability><Antigenic Variation><Antigens><Apical><B-Cell Epitopes><B-Lymphocyte Epitopes><Binding Determinants><Binding Sites><COVID-19 vaccine><COVID-19 virus><COVID19 virus><Case Study><Cholera Enterotoxin CT><Cholera Exotoxin><Cholera Toxin><Choleragen><Clinical Treatment Moab><CoV-2><CoV2><Combining Site><Development><Disease><Disorder><Drugs><Elements><Engineering><Epitopes><Excision><Exposure to><Extirpation><FDA approved><Grippe><HIV><HIV envelope><HIV envelope protein><HIV vaccine><HIV/AIDS><HIV/AIDS Vaccines><Human><Human Immunodeficiency Viruses><Immune><Immune response><Immunes><Immunity><Immunological response><Individuals from minority><Individuals of minority><Infection><Influenza><Integrins><Integrins Extracellular Matrix><Invaded><LAV-HTLV-III><Location><Lymphadenopathy-Associated Virus><Maps><Masks><Mediating><Medication><Membrane Fusion><Minority Groups><Minority People><Minority Population><Minority individual><Modeling><Modern Man><Monoclonal Antibodies><Mucosa><Mucosal Tissue><Mucous Membrane><N-terminal><NH2-terminal><Names><Peripheral><Pharmaceutical Preparations><Position><Positioning Attribute><Pre-Clinical Model><Preclinical Models><Proteins><R-Series Research Projects><R01 Mechanism><R01 Program><RNA Viruses><Reactive Site><Recipe><Removal><Research Grants><Research Project Grants><Research Projects><SARS Virus><SARS corona virus><SARS corona virus 2><SARS coronavirus><SARS-Associated Coronavirus><SARS-CO-V2><SARS-COVID-2><SARS-CoV><SARS-CoV-1><SARS-CoV-2><SARS-CoV-2 vaccine><SARS-CoV2><SARS-Related Coronavirus><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-coronavirus-2 vaccine><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><SHIV><SIV><Severe Acute Respiratory Coronavirus><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome CoV 2 vaccine><Severe Acute Respiratory Syndrome Virus><Severe Acute Respiratory Syndrome corona virus><Severe Acute Respiratory Syndrome coronavirus><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 vaccine><Severe acute respiratory syndrome related corona virus 2><Simian Immunodeficiency Viruses><Site><Structure><Surgical Removal><Testing><Vaccination><Vaccine Clinical Trial><Vaccines><Viral><Virus><Virus-HIV><Wuhan coronavirus><antibody dependent cell mediated cytotoxicity><antibody dependent cytotoxicity><antibody mediated cellular cytotoxicity><antibody-dependent cell cytotoxicity><antibody-dependent cellular cytotoxicity><antibody-mediated cytotoxicity><case report><comparative><coronavirus disease 2019 vaccine><coronavirus disease 2019 virus><coronavirus disease-19 vaccine><coronavirus disease-19 virus><cytotoxic><design><designing><develop a vaccine><develop vaccines><development of a vaccine><developmental><drug/agent><exposed human population><fighting><hCoV19><host response><human exposure><human immunodeficiency virus vaccine><immune system response><immunogen><immunogenic><immunogenicity><immunoresponse><improved><in vivo><insight><life-threatening COVID><life-threatening COVID-19><life-threatening SARS-CoV-2><life-threatening coronavirus disease><life-threatening coronavirus disease 2019><life-threatening severe acute respiratory syndrome coronavirus 2><mAbs><monoclonal Abs><nCoV vaccine><nCoV-19 vaccine><nCoV19 vaccine><nCoV2><name><named><naming><neutralizing antibody><non-human primate><nonhuman primate><novel><pandemic><pandemic disease><pre-clinical><preclinical><pressure><receptor binding><receptor bound><reconstitute><reconstitution><resection><scaffold><scaffolding><serious COVID><serious COVID-19><serious SARS-CoV-2><serious coronavirus disease><serious coronavirus disease 2019><serious severe acute respiratory syndrome coronavirus 2><severe COVID><severe COVID-19><severe COVID19><severe SARS-CoV-2><severe acute respiratory syndrome-CoV><severe coronavirus disease><severe coronavirus disease 19><severe coronavirus disease 2019><severe severe acute respiratory syndrome coronavirus 2><simian HIV><simian human immunodeficiency virus><success><synergism><three dimensional><three dimensional structure><vaccination study><vaccination trial><vaccine against 2019-nCov><vaccine against COVID-19><vaccine against SARS-CoV-2><vaccine against SARS-coronavirus-2><vaccine against Severe Acute Respiratory Syndrome CoV 2><vaccine against Severe acute respiratory syndrome coronavirus 2><vaccine candidate><vaccine candidates against SARS-CoV-2><vaccine development><vaccine efficacy><vaccine for novel coronavirus><vaccine study><vaccine trial><vaccines preventing COVID><vaccines to prevent COVID>